A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: Final report

Journal of Thoracic Oncology

Volumn 1, Issue 9, 2006, Pages 972-978

  Pillot, Giancarlo A ^a   Read, William L ^b   Hennenfent, Kristin L ^c,d   Marsh, Sharon ^a   Gao, Feng ^a   Viswanathan, Avinash ^a   Cummings, Kristopher ^e   McLeod, Howard L ^a,f   Govindan, Ramaswamy ^a,f  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c ST LOUIS COLLEGE OF PHARMACY   (United States)

^d Ortho biotech Pharmaceuticals   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f USA   (United States)

Author keywords

Carboplatin; Irinotecan; Metastasis; Non small cell lung cancer

Indexed keywords

ATROPINE; CARBOPLATIN; CISPLATIN; CYTOCHROME P450 3A4; ENZYME; GLUCURONOSYLTRANSFERASE 1A1; GLUTATHIONE TRANSFERASE P1; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; LOPERAMIDE; MULTIDRUG RESISTANCE PROTEIN 1; PLATINUM; PROTEIN; SEROTONIN 3 ANTAGONIST; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEHYDRATION; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DIZZINESS; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FEVER; GENE; GENOTYPE; HUMAN; HYPERGLYCEMIA; INFECTION; LUNG NON SMALL CELL CANCER; MALAISE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHARMACOGENOMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ADULT; CANCER INVASION; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; PATHOLOGY; PHARMACOGENETICS; PROBABILITY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CAMPTOTHECIN; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PHARMACOGENETICS; PROBABILITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34247897223     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200611000-00009     Document Type: Article

References (41)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Group N-sCLCC. Chemotherapy in non-small cell lung cancer: a metaanalysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
3. Hotta K, Matsuo K, Ueoka H, et al. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004;22:3852-3859.
4. Rosell R, Gatzemeier U, Betticher DC, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002;13:1539-1549.
5. Klastersky J, Sculier JP, Lacroix H, et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 1990;8:1556-1562.
6. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-1717.
7. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
8. Masuda N, Kudoh S, Fukuoka M. Irinotecan (CPT-11): pharmacology and clinical applications. Crit Rev Oncol Hematol 1996;24:3-26.
9. Tsuruo T, Matsuzaki T, Matsushita M, et al. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 1988;21:71-74.
10. Baker L, Khan R, Lynch T, et al. Phase II study of irinotecan (CPT-11) in advanced non-small cell lung cancer (NSCLC). Proc Annu Meet Am Soc Clin Oncol 1997;16:A1658.
11. Bahadori H, Ogretmen B, CM L, et al. Evaluation of irinotecan (CPT-11) and gemcitabine as single agents and in combination in small cell lung cancer cells (Abstract). Proc Am So Clin Oncol 1998;17:477.
12. Douillard J, Ibrahim N, Riviere A, et al. Phase II study of CPT-11 (irinotecan) in non-small cell lung cancer (NSCLC). Proc Annu Meet Am Soc Clin Oncol 1995;14:A1118.
13. Negoro S, Masuda N, Takada Y, et al. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 2003;88:335-341.
14. Masuda N, Fukuoka M, Takada M, et al. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 1992;10:1775-1780.
15. Fukuda M, Oka M, Soda H, et al. Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers. Clin Cancer Res 1999;5:3963-3969.
16. Fukuda M, Oka M, Soda H, et al. Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer. Cancer Chemother Pharmacol 2004;54:573-577.
17. Marsh S, McLeod HL. Pharmacogenetics of irinotecan toxicity. Pharmacogenomics 2004;5:835-843.
18. Humerickhouse R, Lohrbach K, Li L, et al. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 2000;60:1189-1192.
19. Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000;60:6921-6926.
20. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22:1382-1388.
21. Stoehlmacher J, Ghaderi V, Iobal S, et al. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 2001;21:3075-3079.
22. Stoehlmacher J, Park DJ, Zhang W, et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002;94:936-942.
23. Stoehlmacher J, Park DJ, Zhang W, et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004;91:344-354.
24. Park DJ, Stoehlmacher J, Zhang W, et al. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001;61:8654-8658.
25. Chu E, DeVita V. Principles of Cancer Management: Chemotherapy, 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2001.
26. Marsh S, King CR, Garsa AA, et al. Pyrosequencing of clinically relevant polymorphisms. Methods Mol Biol 2005;311:97-114.
27. Saeki M, Saito Y, Jinno H, et al. Comprehensive UGT1A1 genotyping in a Japanese population by pyrosequencing. Clin Chem 2003;49:1182-1185.
28. King CR, Yu J, Freimuth RR, et al. Interethnic variability of ERCC2 polymorphisms. Pharmacogenomics J 2005;5:54-59.
29. Rouits E, Boisdron-Celle M, Dumont A, et al. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 2004;10:5151-5159.
30. FDA clears genetic test that advances personalized medicinetest helps determine safety of drug therapy. Available at http://www.fda.gov/bbs/topics/ NEWS/2005/NEW01220.html. Accessed November 27, 2005.
31. Hasegawa Y, Sarashina T, Ando M, et al. Rapid detection of UGT1A1 gene polymorphisms by newly developed invader assay. Clin Chem 2004;50:1479-1480.
32. Inoue T, Ishida T, Sugio K, et al. Glutathione S transferase pi is a powerful indicator in chemotherapy of human lung squamous-cell carcinoma. Respiration 1995;62:223-227.
33. Masuda N, Fukuoka M, Fujita A, et al. A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group. Br J Cancer 1998;78:251-256.
34. Mori K, Machida S, Yoshida T, et al. A phase II study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 1999;43:467-470.
35. DeVore RF, Johnson DH, Crawford J, et al. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 1999;17:2710-2720.
36. Kakolyris S, Kouroussis C, Souglakos J, et al. Cisplatin and irinotecan (CPT-11) as second-line treatment in patients with advanced non-small cell lung cancer. Lung Cancer 2001;4(34 Suppl):S71-S76.
37. Jagasia MH, Langer CJ, Johnson DH, et al. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study. Clin Cancer Res 2001;7:68-73.
38. Ueoka H, Tanimoto M, Kiura K, et al. Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study Group. Br J Cancer 2001;85:9-13.
39. Takeda K, Takifuji N, Uejima H, et al. Phase II study of irinotecan and carboplatin for advanced non-small cell lung cancer. Lung Cancer 2002;38:303-308.
40. Cardenal F, Domine M, Massuti B, et al. Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study. Lung Cancer 2003;39:201-207.
41. Georgoulias V, Agelidou A, Syrigos K, et al. Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study. Br J Cancer 2005;93:763-769.